CABA-201
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for CABA-201, covering 2025-10-31 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis [Phase 1, Phase 2]